 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 80
|
|
-
Gene Bridges licenses Red/ET Recombineering to Novozymes
(23 Apr 2008)
Gene Bridges GmbH announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to ......
-
Biovitrum and Symphogen Initiates a Second Clinical study with a Novel Treatment of Hemolytic Diseases
(21 Apr 2008)
Biovitrum AB and Symphogen A/Sannounced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy ......
-
Novel insights into HuMax-EGFr mechanisms of action
(17 Apr 2008)
Genmab A/S announced new insights showing that HuMax-EGFr(TM) (zalutumumab) locks epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and ......
-
Post-exposure vaccination with IMVAMUNE protects against lethal poxvirus infection
(14 Apr 2008)
In studies with Bavarian Nordic's new and innovative third-generation smallpox vaccine, IMVAMUNE®, scientists from Bavarian Nordic have for the first time demonstrated a therapeutic effect of a smallpox vaccine, days after infection. With the ......
-
Peter Edman new Chief Scientific Officer at Biovitrum AB
(28 Mar 2008)
Peter Edman, PhD, Associate Professor, 54, will join Biovitrum as Chief Scientific Officer. He is leaving his current position as Vice President and Global Project Director, Global Development, at AstraZeneca. Peter Edman has previously held a ......
-
Nature publishes study by Santaris Pharma scientists and collaborators: LNA-mediated microRNA silencing in non-human primates
(28 Mar 2008)
Santaris Pharma announced the publication in Nature of a peer-reviewed study entitled "NA-mediated microRNA silencing in non-human primates". The paper is the first demonstration of microRNA silencing in non-human primates, providing an ......
-
Pharmexa and Ichor Medical Systems enter into an agreement to co-develop multiple DNA vaccines delivered by electroporation
(12 Mar 2008)
Pharmexa and Ichor have entered into an agreement to co-develop multiple DNA vaccines to combat important diseases of high unmet medical need. It is well recognized that in vivo electroporation is a promising means of enhancing the potency of ......
-
Claus Bræstrup resigns as President and CEO of Lundbeck
(10 Mar 2008)
Claus Bræstrup resigned from his position as President and CEO of H. Lundbeck A/S and will step down immediately. Until a replacement has been found, Per Wold-Olsen, Chairman of the Supervisory Board, will act as executive chairman. The ......
-
Genmab and Pepscan to identify human antibodies against intractable targets
(05 Mar 2008)
Genmab A/S and Pepscan announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets. Intractable targets include those that are difficult to address using commonly ......
-
Lundbeck further strengthens pipeline by moving Lu AA34893 into clinical phase II
(20 Feb 2008)
H. Lundbeck A/S has decided to investigate Lu AA34893 for the treatment of bipolar disorder. The decision is based on positive pre-clinical results as well as positive conclusion of the phase I trials in healthy individuals. The first patients ......
|
|
|
Top